We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Early Weight-Bearing After the Lapiplasty Procedure (ALIGN3D)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03740282
Recruitment Status : Active, not recruiting
First Posted : November 14, 2018
Last Update Posted : April 11, 2022
Information provided by (Responsible Party):
Treace Medical Concepts, Inc.

Brief Summary:

The objectives of this study are to evaluate the following outcomes of the Lapiplasty® Procedure for patients in need of hallux valgus surgery:

  • The study will determine the radiographic recurrence of hallux valgus and the timing of failure following hallux valgus correction with the Lapiplasty® Procedure.
  • The study will determine whether the Lapiplasty® Procedure effectively corrects anatomical alignment of the 1st metatarsal and sesamoids in all three planes.
  • The study will assess whether early weight-bearing after the Lapiplasty® Procedure affects the union rates or causes loss of 3-plane correction.
  • The study will evaluate the quality of life and pain scores following the Lapiplasty® Procedure.

Condition or disease Intervention/treatment Phase
Hallux Valgus Bunion Device: Lapiplasty Not Applicable

Detailed Description:

Each subject will undergo the Lapiplasty® Procedure. The key surgical steps of the Lapiplasty® Procedure are releasing the 1st TMT joint, anatomical correction of the 3-plane deformity, bone preparation using the Lapiplasty® Cut Guide , provisional fixation and multiplanar permanent fixation with the BIPLANAR™ Plate.

It is common for people who undergo a Lapidus Arthrodesis to be non-weight-bearing for 6-8 weeks following the surgical procedure. This time allows the bones to properly fuse together. During this 6-8 week period, people can be limited in the typical day-to-day activities they participate in, such as walking, shopping and working.

The Lapiplasty® System Implants may allow subjects to bear weight earlier than traditional procedures without negatively effecting healing/union of the joint. By allowing people to bear weight earlier than traditional methods, it is possible that people will have the opportunity to resume typical day-to-day activities faster than usual.

This study will investigate the Lapiplasty® Procedure and the Lapiplasty® System Implants with early weight-bearing. The study preference is that subject will be placed in a walking CAM boot and allowed to start protected weight bearing no later than 3 weeks after surgery. Subject can begin protected bearing weight in a CAM boot as early as the day of surgery. Subject will return to weight-bearing in shoe (running or another athletic shoe) and full unrestricted activity as directed by the physician based on the clinical stability and subject ability to safely begin weight-bearing and unrestricted activities.

Recommended Approach for Post-Operative Care and Weight-Bearing Instructions

  • Subject may be either bandaged, put in splint/cast or put in CAM boot at the time of surgery. If subject is fitted with CAM boot at discharge, the patient should be provided instructions on how to begin protected weight-bearing.
  • Subject is instructed to remain off the operative foot as much as possible for the first few days post-op. This is to limit bleeding and swelling and to allow soft tissues to recover.
  • Subject may leave the surgery facility with crutches, walker, rolling knee scooter or wheelchair.
  • At the first post-op visit (0-3 weeks), bandages are removed, and the subject can be allowed to shower. Subject may wear an athletic sock. No bandages or splints are needed. The subject should be reminded of post-op care of the foot/surgical site.
  • At the first post-op visit (0-3 weeks), the subject is fitted with a CAM boot (if the subject was not fitted for a CAM boot at discharge). Subject should be provided with instructions on how to begin protected weight-bearing in the CAM boot and acceptable activities:

    • Patient is instructed to put weight on foot as tolerated in the restrictive boot.
    • Patient is instructed not to roll forward onto the big toe and should remain on flat foot.
    • Patient is instructed to remove the CAM boot multiple times daily and perform range of motion exercises for ankle and foot.
  • At the 6 week post-op visit, if the subject is clinically stable, subject can transition from the boot to a shoe (running or another athletic shoe). The transition from boot to shoe may occur over a period of days/weeks, depending on subject healing and tolerance. Subject is instructed that they can walk normally but are not to stand on toes, run, jump or do any other high impact activity
  • At the 4 month post-op visit, subject is allowed to begin low impact exercise if they are clinically stable.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 183 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Prospective Clinical StuDy of Tri-planar Tarsometatarsal (TMT) ArthroDesIs With Early WeiGht-BeariNg After Lapiplasty ProcDure (ALIGN3D)
Actual Study Start Date : November 6, 2018
Estimated Primary Completion Date : May 31, 2023
Estimated Study Completion Date : May 31, 2026

Resource links provided by the National Library of Medicine

MedlinePlus Genetics related topics: Bunion
MedlinePlus related topics: Body Weight

Arm Intervention/treatment
Experimental: Lapiplasty
All study participants receiving Lapiplasty procedure
Device: Lapiplasty
Patients 14 years through 58 years with symptomatic hallux valgus who are treated with the Lapiplasty System will begin weight-bearing by 3 weeks and follow a defined post-operative protocol.

Primary Outcome Measures :
  1. Radiographic recurrence of hallux valgus [ Time Frame: 24 Months ]
    Defined as IMA ≥ 12, HVA ≥ 20 and TSP as ≥ 4 at 24 Months post Lapiplasty Procedure

Secondary Outcome Measures :
  1. Change in radiographic angular/positional alignment before and after the Lapiplasty Procedure [ Time Frame: Pre-operatively, 6 Weeks, 4 Months, 6 Months, 12 Months, 24 Months, 36 Month, 48 Months, 60 Months ]
    Intermetatarsal Angle (IMA), Hallux Valgus Angle (HVA) and Tibial Sesamoid Position (TSP)

  2. Clinical/radiographic healing [ Time Frame: 12 Months ]
    Evaluate clinical/radiographic healing (union vs non-union). Non-union defined as lucency at TMT joint, hardware failure and/or loss of correction, plus clinical pain at first TMT joint at 12 Months post-Lapiplasty Procedure

  3. Clinical complications [ Time Frame: 24 Months ]
    Complications due to the Lapiplasty procedure device or post-operative protocol or health conditions that could affect other health outcomes

  4. Time to start of weight-bearing in boot [ Time Frame: 0-3 Weeks ]
    The time needed for a study subject to begin bearing weight in a boot after the Lapiplasty Procedure

  5. Time to start of weight-bearing in shoes [ Time Frame: 0-12 Weeks ]
    The time needed for a study subject to begin bearing weight in a shoe after the Lapiplasty Procedure

  6. Time to return to full unrestricted activity [ Time Frame: 6 Weeks to 12 Months ]
    The time needed for a study subject to return to full unrestricted activity after the Lapiplasty Procedure

  7. Change in Visual Analog Scale (VAS) Pain Score [ Time Frame: Pre-operatively, 6 Weeks, 4 Months, 6 Months, 12 Months, 24 Months, 36 Month, 48 Months, 60 Months ]
    Patient reported foot pain intensity/0 (no pain) - 10 (worst possible pain)

  8. Change in PROMIS-29 score across multiple time-points [ Time Frame: Pre-operatively, 6 Months, 12 Months, 24 Months ]
    Patient-Reported Outcomes Measurement Information System (PROMIS-29 Profile v2.1)/lowest possible score 29 - highest possible score 145. High scores mean more of the concept being measured.

  9. Change in PROMIS-25 score across multiple time-points [ Time Frame: Pre-operatively, 6 Months, 12 Months, 24 Months ]
    Patient-Reported Outcomes Measurement Information System (PROMIS-25 Profile v2.0)/lowest possible score 25 - highest possible score 135. High scores mean more of the concept being measured.

  10. Change in MOxFQ Foot Problems score across multiple time-points [ Time Frame: Pre-operatively, 6 Months, 12 Months, 24 Months ]
    Manchester-Oxford Foot Questionnaire (MOxFQ)/0 (minimum raw score) - 64 (maximum raw score). Raw score is converted to a metric of 0 - 100 with higher score representing greater severity

  11. Change in Range of Motion [ Time Frame: 12 Months, 24 Months ]
    1st MTP dorsiflexion and 1st MTP plantarflexion

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   14 Years to 58 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Male and females between the ages 14 and 58 years at the time of consent
  • Closed physeal plates at the time of consent
  • Intermetatarsal angle is between 10.0 ̊ - 22.0 ̊
  • Hallux valgus angle is between 16.0 ̊ - 40.0 ̊
  • Willing and able to adhere to early weight-bearing instructions post-operatively
  • Capable of completing self - administered questionnaires
  • Acceptable surgical candidate, including use of general anesthesia
  • Female patients must be of non-child bearing potential or have a negative pregnancy test within 7 days prior to index procedure
  • Willing and able to schedule index procedure within 3 months of consent and able to return for scheduled follow-up visits
  • Willing and able to provide written informed consent

Exclusion Criteria:

  • Previous surgery for hallux valgus on operative side
  • Previous surgeries on operative foot involving fusion of foot or ankle joints (other than hammertoe or lesser toes/digits)
  • Additional arthrodesis outside the first tarsometatarsal joint (other than: arthrodesis between the medial cuneiform and intermediate cuneiform and/or base of 2nd metatarsal; arthrodesis of hammertoe proximal interphalangeal joint or lesser toes/digits)
  • Moderate or Severe osteoarthritis of the MTP joint based on radiographic imaging (including lack of evident crista) or positive grind test
  • Symptomatic flatfoot or asymptomatic flatfoot (defined as calcaneal inclination <5 ̊and talonavicular subluxation/uncovering >50%)
  • BMI >40 kg/m²
  • Current nicotine user, including current use of nicotine patch
  • Current clinical diagnosis of diabetes with fasting plasma glucose > 126 mg/dL and/or HbA 1c ≥7.0
  • Current clinical diagnosis of peripheral neuropathy or by assessment on 4 - point monofilament test
  • Current clinical diagnosis of fibromyalgia
  • Current clinical diagnosis of Complex Regional Pain Syndrome/Reflex Sympathetic Dystrophy (CRPS/RSD)
  • Current uncontrolled hypothyroidism
  • Previously sensitized to titanium
  • Currently taking oral steroids or rheumatoid biologics
  • Currently taking immunosuppressant drugs
  • Insufficient quantity or quality of bone to permit stabilization, conditions that retard healing (not including pathological fractures) and conditions causing poor blood supply such as peripheral vascular disease
  • Active, suspected or latent infection in the affected area
  • Use of synthetic or allogenic bone graft substitutes
  • Current diagnosis of metatarsus adductus (defined as MAA ≥ 23 ̊)
  • Scheduled to undergo a same - bilateral procedure. Patient agrees to refrain from the Lapiplasty® Procedure (or other hallux valgus procedures) on contralateral foot for minimum of 6 months post index procedure
  • Patient has previously been enrolled into this study for a contralateral procedure
  • Scheduled for any concomitant procedure that would alter patient's ability to early weight-bear post-procedure
  • Patient is actively involved with a workman's compensation case or is currently involved in litigation
  • Patient is currently or has participated in a clinical study in the last 30 days prior to signing
  • Patient has a condition or finding that, in the opinion of the Investigator, may jeopardize the patient's well-being, the soundness of this clinical study, or could interfere with provision of informed consent, completion of tests, therapy, or follow-up

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03740282

Layout table for location information
United States, Colorado
Foot & Ankle Center of Northern Colorado
Greeley, Colorado, United States, 80634
United States, Iowa
Foot & Ankle Center of Iowa
Ankeny, Iowa, United States, 50023
United States, Missouri
Jefferson City Medical Group, P.C.
Jefferson City, Missouri, United States, 65109
United States, Nevada
Desert Orthopaedic Center
Las Vegas, Nevada, United States, 89121
United States, Pennsylvania
University of Pennsylvania/Penn Medicine
Philadelphia, Pennsylvania, United States, 19106
United States, Texas
UT Southwestern
Dallas, Texas, United States, 75390
Stonebriar Foot & Ankle
Frisco, Texas, United States, 75034
Sponsors and Collaborators
Treace Medical Concepts, Inc.
Layout table for investigator information
Principal Investigator: Dane Wukich, MD UTSW
Layout table for additonal information
Responsible Party: Treace Medical Concepts, Inc.
ClinicalTrials.gov Identifier: NCT03740282    
Other Study ID Numbers: CP2018-1
First Posted: November 14, 2018    Key Record Dates
Last Update Posted: April 11, 2022
Last Verified: September 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Product Manufactured in and Exported from the U.S.: No
Keywords provided by Treace Medical Concepts, Inc.:
early weight-bearing
hallux valgus
Additional relevant MeSH terms:
Layout table for MeSH terms
Hallux Valgus
Foot Deformities
Musculoskeletal Diseases
Foot Deformities, Acquired